Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition

Company Was First To Develop An Ebola Vaccine

 
• By Andrew McConaghie

While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.

Merck
Merck will acquire Themis, whose vaccine is expected to enter Phase I trials later this year

More from COVID-19

More from Scrip